No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
AU Stock MarketDetailed Quotes
CURE Global X S&P Biotech ETF
- 51.670
- +0.980+1.93%
20min DelayNot Open Jul 24 16:00 AET
51.670High50.500Low
51.670High50.500Low1.01KVolume50.500Open50.690Pre Close51.90KTurnover54.00052wk High0.12%Turnover Ratio824.01KShares34.75052wk Low--EPS TTM42.58MFloat Cap63.958Historical High--P/E (Static)824.01KShs Float31.059Historical Low--EPS LYR2.31%Amplitude--Dividend TTM--P/B1Lot Size--Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BioMarin Gets Expanded FDA Approval for CLN2 Therapy Brineura
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Albemarle Is Out of Wells Fargo's Signature Picks
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain